Pfizer 4Q Revenues: $14.2 billion (-41%) 4Q Loss: $3.4 billion (earnings were $5.0 billion 4Q22) FY Revenues: $58.5 billion (-42%) FY Earnings: $2.1 billion (-93%) Comments: Decline in Comirnaty and Paxlovid revenues drove 42% operational decrease in the quarter. Biopharmaceuticals business sales were down 42% in the quarter to $13.9 billion. Primary Care sales were down 60% to $7.0 billion. Specialty care sales were up 11% to $3.9 billion. Oncology sales were down 3% to $2.9 billion in th...